Dr. Amol Kulkarni is an experienced Microbiology researcher in the field of antibacterial drug discovery. He has an extensive hands on experience of in vitro and in vivo aspects of new drug discovery. He has worked on many clinically important bacterial pathogens such as E.coli, K. pneumoniae, P.aeruginosa, A. baumannii, Streptococcus spp, staphylococcus spp, etc. His experience in In vitro evaluation of new drugs comprises Minimum inhibitory concentrations (MIC), time kill studies, intracellular killing of bacterial pathogens, biofilm studies, etc. With detailed insight in the mouse infection models of bacteria, he has a good understanding of pathogenicity of different bacterial pathogens in variety of body compartments such as lungs, thigh, blood, kidney, bone and joint and skin. Determination of Preclinical PK/PD aspects of new drugs is the main area of interest of his studies. He has evaluated and differentiated different classes of clinically available as well as under development antibacterial agents using single compartment model of IVPM. His main work is with cephalosporin and fluoroquinolone classes of antibacterial agents. His work is published in international conferences such as Microbes (former inter science conference in antibiotics and antibacterial agents, ICAAC); ID week and ECCMID which includes work on Novel mechanism of action of new drugs, in vivo evaluation of these drugs, new classes such as ketolides, fourth generation cephalosporins, Carbapenems, etc. His work is also published in the journal of Antimicrobial agents and chemotherapy (AAC).
Apart from research in drug discovery, he is a science blogger as well. His blog has won a prestigious award in blog writing by ABP news network.
Dr. Amol Kulkarni's research interests include Bacterial pathogenicity, mouse infection models of bacteria, IVPM studies, emergence of mechanism of resistance to different antibiotics, etc.